Phase II trial of GDP therapy (gemcitabine, cisplatin and dexamethasone) in patients with refractory or recurrence non-Hodgkin's lymphoma having a history of more than 2 regimens.
Phase 2
- Conditions
- non-Hodgkin's lymphoma
- Registration Number
- JPRN-UMIN000013588
- Lead Sponsor
- Kyoto Prefectural University of Medicine Department of Hematology and Oncology,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Interstitial pneumonitis or pulmonary fibrosis. 2. Prior radiotherapy for the lungs. 3. Uncontrollable diabetes. 4. Uncontrollable heat disease. 5. Uncontrollable infection. 6. History of severe drug allergy. 7. Severe renal disorder. 8. Large quantity of pleural, abdominal or cardiac effusion. 9. Positive for HBs antigen. 10. Positive for HCV antibody. 11. Severe mental disease. 12. Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. 13. Women who are pregnant or breastfeeding. Men/women who are unwilling to avoid pregnancy. 14. Inadequate for study enrollment by the physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method Complete Response Rate Event-Free Survival Progression-Free Survival Safety Completion Rate